Number of shares and votes in Calliditas Therapeutics December 30, 2022 08:00 CET Regulatory Read more
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan December 13, 2022 08:00 CET Regulatory Read more
Calliditas Therapeutics’ nomination committee composition for the AGM 2023 October 21, 2022 10:00 CET Regulatory Read more
European Commission approves Kinpeygo® for adults with primary IgA nephropathy July 15, 2022 17:00 CET Regulatory Read more
Issuance and repurchase of C-shares to establish an at-the-market program June 20, 2022 21:15 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 19, 2022 16:30 CET Regulatory Read more
Calliditas receives positive CHMP opinion in IgA nephropathy May 19, 2022 14:30 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 14, 2022 08:30 CET Regulatory Read more
